Abstract: The present invention provides an aptamer that binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a medicament containing the aptamer, or a complex containing the aptamer and a functional substance, a diagnosing drug and labeling agent and the like.

Abstract: The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond, X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, and X3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Abstract: Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.

Abstract: A paper folding device is configured so that a folding line is always formed at a predetermined position of paper sheets. A paper supply section is provided with a conveyor belt for conveying paper sheets (P) sequentially supplied from a paper sheet stack. A guide plate (4) for aligning the positions of the conveyed paper sheets is provided on a conveying surface of the conveyor belt. A paper folding section has a buckle (10) comprising an outer frame (11) and bars (12) which extend between opposite sides (11a, 11b) of the outer frame and are arranged at intervals from each other. Paper sheet introducing gaps extended in the direction of the length of the bars are provided in the buckle.

Abstract: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Abstract: A process for producing a caking additive for coke production, the process including a step of extracting a solvent deasphalted pitch that can be used as a caking additive for coke production from a residue containing at least one of an atmospheric residue obtained by atmospheric distillation of a crude oil and a vacuum residue obtained by atmospheric distillation and vacuum distillation of a crude oil, wherein the extraction is performed using, as a solvent, a light reformate obtained by catalytic reforming a naphtha fraction that is fractionated from a crude oil by atmospheric distillation of the crude oil.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.

Abstract: Provided is a presentation system in which data communication is performed between presenter-side viewing terminal with which a presenter views a slide image prepared in advance to make a presentation; and an audience-side viewing terminal with which an audience views the slide image, whereby the slide image designated at the presenter-side viewing terminal is displayed on the audience-side viewing terminal. The presentation system includes an audience-side portable terminal that receives an input operation by the audience. Upon receipt of the input operation by the audience, the audience-side portable terminal stores memo information indicating a content of the input operation; obtains a slide ID used to identify the slide image being displayed on the audience-side viewing terminal; and records the memo information in association with the slide ID.

Abstract: An automatic transmission damper mechanism provided between a first hydraulic passage (23) to which an oil (L) is supplied and a second hydraulic passage (24) from which the oil (L) is supplied to a friction element (18) has: a container (8) provided between the first and second hydraulic passages (23, 24); a slide member (11) provided in the container (8) such that it can slide therein; and an elastic member (9) provided between an inner face of the container (8) and the slide member (11). The container (8) has a pressure chamber (28) defined by an inner face of the container (8) and the slide member (11) and communicating with a branch hydraulic passage (25) branching from the first hydraulic passage (23), and the slide member (11) has a communication hole (15) through which the first and second hydraulic passages (23, 24) are placed in communication by the elastic member (9) contracting under the pressure of the oil (L) supplied into the pressure chamber (28) through the branch hydraulic passage (25).

Abstract: The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.

Abstract: Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: A paper folding device is configured so that a folding line is always formed at a predetermined position of paper sheets. A paper supply section is provided with a conveyor belt for conveying paper sheets (P) sequentially supplied from a paper sheet stack. A guide plate (4) for aligning the positions of the conveyed paper sheets is provided on a conveying surface of the conveyor belt. A paper folding section has a buckle (10) comprising an outer frame (11) and bars (12) which extend between opposite sides (11a, 11b) of the outer frame and are arranged at intervals from each other. Paper sheet introducing gaps extended in the direction of the length of the bars are provided in the buckle.

Abstract: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: Provided is a business management system that performs a business management of a plurality of stores in a collective manner. The system includes a first terminal device, a second terminal device, and a management server. The first terminal device sets a time at which a first operation is inputted by a visitor via an input device installed in the store as a visiting time, and generates a visitor number for sequentially leading the visitor while associating the visitor number with the visiting time. The second terminal device inputs the visitor number and a preset second operation. The management server obtains a service time (a time period from a service start time till a service end time) and a waiting time (a time period from the visiting time till the service start time), and aggregates the service time and the waiting time on a time-series basis for each store.

Abstract: Provided is a high-quality aptamer against midkine. An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.

Abstract: A process for producing a caking additive for coke production, the process including a step of extracting a solvent deasphalted pitch that can be used as a caking additive for coke production from a residue containing at least one of an atmospheric residue obtained by atmospheric distillation of a crude oil and a vacuum residue obtained by atmospheric distillation and vacuum distillation of a crude oil, wherein the extraction is performed using, as a solvent, a light reformate obtained by catalytic reforming a naphtha fraction that is fractionated from a crude oil by atmospheric distillation of the crude oil.